Unique responses of limbic met-enkephalin systems to low and high doses of methamphetamine.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 11423086)

Published in Brain Res on June 29, 2001

Authors

M E Alburges1, K A Keefe, G R Hanson

Author Affiliations

1: Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, 30 So. 2000 E., Room 201, Salt Lake City, UT 84112-5820, USA. m.e.alburges@m.cc.utah.edu

Articles by these authors

Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem (1989) 2.75

Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem (1999) 2.30

Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem (2000) 1.49

Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol (2000) 1.46

D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J Neurosci (1995) 1.37

Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther (1985) 1.29

Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol (1999) 1.27

Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther (1997) 1.26

Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther (2001) 1.20

The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol (1986) 1.14

Human parvovirus-associated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol (1986) 1.13

Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci (2001) 1.13

Quantitative near-infrared spectroscopy of cervical dysplasia in vivo. Hum Reprod (1999) 1.12

Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther (2001) 1.11

Characterization of DorC from Rhodobacter capsulatus, a c-type cytochrome involved in electron transfer to dimethyl sulfoxide reductase. J Biol Chem (1999) 1.08

Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol (1998) 1.07

Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur J Neurosci (1999) 1.05

Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem (2000) 1.04

Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther (2000) 1.02

Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther (1986) 1.01

Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience (2001) 0.99

Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J Pharmacol Exp Ther (2001) 0.99

Arc mRNA induction in striatal efferent neurons associated with response learning. Eur J Neurosci (2007) 0.98

Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol (1985) 0.97

The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem (2000) 0.97

Effect of methamphetamine on neurotensin concentrations in rat brain regions. J Pharmacol Exp Ther (1987) 0.97

Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Res (1994) 0.96

Computer simulation of magnetic resonance spectra employing homotopy. J Magn Reson (1998) 0.96

Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther (1997) 0.96

Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res (1998) 0.96

Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem (1999) 0.96

Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis. Brain Res (1996) 0.95

Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens. Eur J Pharmacol (1989) 0.95

Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J Pharmacol Exp Ther (1997) 0.94

Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology (1987) 0.94

A purple acid phosphatase from sweet potato contains an antiferromagnetically coupled binuclear Fe-Mn center. J Biol Chem (2001) 0.93

Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology (1987) 0.92

Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol (1997) 0.92

Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects. J Pharmacol Exp Ther (1994) 0.92

Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther (1988) 0.91

Stimulation of non-neuronal cell proliferation in vitro by mitogenic factors present in highly purified sympathetic neurons. Brain Res (1978) 0.91

MDMA: historical perspectives. Ann N Y Acad Sci (1990) 0.90

Effects of cocaine on extrapyramidal and limbic dynorphin systems. J Pharmacol Exp Ther (1990) 0.90

Elevation of substance P-like immunoreactivity in rat central nervous system by protease inhibitors. J Neurochem (1980) 0.88

A purified ferredoxin from Giardia duodenalis. Eur J Biochem (1994) 0.88

Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neuroscience (2005) 0.88

Mutational analysis of the dimethylsulfoxide respiratory (dor) operon of Rhodobacter capsulatus. Microbiology (1999) 0.88

Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems of the rat brain. Brain Res (1989) 0.87

Cocaine and methamphetamine differentially affect opioid peptide mRNA expression in the striatum. J Neurochem (2000) 0.87

Methamphetamine-induced depression of monoamine synthesis in the rat: development of tolerance. J Neurochem (1985) 0.87

A rapid and reversible change in dopamine transporters induced by methamphetamine. Eur J Pharmacol (1997) 0.87

Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens. J Pharmacol Exp Ther (1996) 0.87

HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3. Br J Cancer (2003) 0.86

Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J Pharmacol Exp Ther (1994) 0.86

Neuroendocrine actions and regulation of hypothalamic neuropeptide Y during lactation. Peptides (2007) 0.86

Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine. Eur J Pharmacol (2000) 0.86

Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity. Neuroscience (1987) 0.86

Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. J Pharmacol Exp Ther (1992) 0.86

Neurochemical basis of neurotoxicity. Neurotoxicology (1990) 0.86

Mechanisms for tolerance to methamphetamine effects. Neuropharmacology (1996) 0.85

Preparation and partial characterization of highly purified primary cultures of neurons and non-neuronal (glial) cells from embryonic chick cerebral hemispheres and several other regions of the nervous system. Brain Res (1982) 0.85

Contrasting responses by basal ganglia met-enkephalin systems to low and high doses of methamphetamine in a rat model. J Neurochem (2001) 0.84

Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway. Brain Res Mol Brain Res (1999) 0.84

m-THPC-mediated photodynamic therapy (PDT) does not induce resistance to chemotherapy, radiotherapy or PDT on human breast cancer cells in vitro. Photochem Photobiol (1998) 0.83

Methcathinone: an initial study of its effects on monoaminergic systems. J Pharmacol Exp Ther (1996) 0.83

Changes in the limbic neurotensin systems induced by dopaminergic drugs. Eur J Pharmacol (1988) 0.83

Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. Eur J Pharmacol (1989) 0.83

A comparison of two factors affecting the proliferation of non-neuronal (glial) cells in vitro. Brain Res (1980) 0.83

Expression of the core exon-junction complex factor eukaryotic initiation factor 4A3 is increased during spatial exploration and striatally-mediated learning. Neuroscience (2012) 0.83

Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog. Eur J Pharmacol (1989) 0.82

Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons. Neuroscience (2001) 0.82

Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. Eur J Pharmacol (1989) 0.82

Studies on the mechanism of tolerance to methamphetamine. Brain Res (1985) 0.82

Molybdate-dependent expression of dimethylsulfoxide reductase in Rhodobacter capsulatus. FEMS Microbiol Lett (2000) 0.82

Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine. Brain Res (1999) 0.81

Characterization of the inhibitor complexes of cobalt carboxypeptidase A by electron paramagnetic resonance spectroscopy. Biochemistry (1989) 0.81

Effects of stimulants of abuse on extrapyramidal and limbic neuropeptide Y systems. J Pharmacol Exp Ther (1999) 0.81

Mechanisms of chemotransmission in the mammalian carotid body. Prog Brain Res (1988) 0.81

Cloning and sequence analysis of the dimethylsulfoxide reductase structural gene from Rhodobacter capsulatus. Biochim Biophys Acta (1996) 0.80

Dopamine-mediated gene regulation in the striatum. Adv Pharmacol (1998) 0.80

Detection of hydroxyl and carbon-centred radicals by EPR spectroscopy after ischaemia and reperfusion of the rat kidney. Free Radic Res (1996) 0.80

Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Amino Acids (1998) 0.80

Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters. Brain Res (2000) 0.79

Release of vasoactive intestinal peptide and neuropeptide Y from canine heart. Am J Physiol (1993) 0.79

Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems. Brain Res (1992) 0.79

Effects of conantokins on L-3,4-dihydroxyphenylalanine-induced behavior and immediate early gene expression. Eur J Pharmacol (2000) 0.79

Examination of the involvement of protein kinase A in D2 dopamine receptor antagonist-induced immediate early gene expression. J Neurochem (2001) 0.79

Characterization of a molybdenum cofactor biosynthetic gene cluster in Rhodobacter capsulatus which is specific for the biogenesis of dimethylsulfoxide reductase. Microbiology (1999) 0.79

Neurotoxicity of amphetamines and their metabolites. NIDA Res Monogr (1997) 0.79

Effects of MK-801 on D1 dopamine receptor-mediated immediate early gene expression in the dopamine-depleted striatum. Brain Res (2000) 0.79

Autoradiographic analysis of muscarinic cholinergic and serotonergic receptor alterations following methamphetamine treatment. Brain Res Bull (1987) 0.78

A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol (1987) 0.78

Expression of antigens associated with small cell carcinoma of the lung on hematopoietic progenitor cells. Cancer Res (1987) 0.78

Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems. J Pharmacol Exp Ther (1989) 0.78

Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems. J Pharmacol Exp Ther (1981) 0.78